Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.
